Diabetic nephropathy (DN) develops in approximately 30% of subjects with type 1 diabetes. Control of hypertension, blood sugar levels, and albuminuria through the use of ACE inhibitors are key strategies in attenuating the progressive decline in renal function in patients with DN. 1 While tight glycaemic and blood pressure control are important in delaying the progression of nephropathy there is a need to treat the underling fibrosis that leads to end organ failure. 2 Pro-fibrotic growth factors including plateletderived growth factor (PDGF), connective tissue growth factor (CTGF), and transforming growth factor  (TGF-) have been identified as cytokines that stimulate the deposition of collagen in the kidney. [3] [4] [5] It has been estimated that some 45% of all deaths in the developed world may have an underlying pathology of aberrant fibrosis. 6 However, this mode of action has only recently been targeted explicitly in the clinic, with the approval of perfenidone for idiopathic pulmonary fibrosis. 7 Tranilast (1), a cinnamoylanthranilate, has been used in Japan and South Korea for over 20 years to treat allergic disorders, hypertrophic scars and scleroderma ( Figure 1A ). Tranilast inhibits pro-fibrotic growth factors including TGF-, 8, 9 PDGF, 9 and CTGF, 10 and thus is an antifibrotic agent. Structureactivity relationships of cinnamoylanthranilates have led to the development of several analogues including FT011 (2) and FT023 (3). 11 FT011 prevents collagen synthesis in TGF- and PDGF-BB stimulated mesangial cells in vitro. 12 In an advanced model of DN, the streptozotocin-diabetic Ren-2 rat, FT011 reduced albuminuria, glomerulosclerosis and tubulointerstitial fibrosis. 12 Reflecting the ability of FT011 to inhibit the action of locally-active growth factors involved in fibrosis, FT011 also attenuates cardiac remodelling and dysfunction in experimental diabetic cardiomyopathy. 13 The related compound FT023 significantly attenuated the increased heart weight:bodyweight ratio in diabetic Ren-2 rats, and attenuated diastolic dysfunction. 14 Further, FT011 treatment attenuates Armanni-Ebstein lesions (a key morphological feature of DN) in a rat model of diabetes. 15 Recently, FT011 has entered into clinical development for the treatment of DN. The PRESTO (prevention of restenosis with tranilast and its outcomes) study sought to use tranilast to prevent adverse clinical events including re-stenosis for patients undergoing stent-based and stent-free coronary revascularization. 16 At the highest doses of tranilast, a range of reversible abnormalities were identified including hyperbilirubinemia, increased alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), decline in haemoglobin, and increased serum creatinine. 17 The molecular bases of these issues are incompletely understood; however, it appears that hyperbilirubinemia is especially prevalent within patients with Gilbert's syndrome, in which carriers express lower than normal levels of UGT1A1. 18, 19 Tranilast undergoes Phase I metabolism to the demethylated derivative N-3 (4), and both tranilast and N-3 undergo phase II glucuronidation catalyzed by UGT1A1 ( Figure 1B) . 20 Consequently, tranilast-induced hyperbilirubinemia appears to result from inhibition of bilirubin-metabolism by glucuronosyltransferase UGT1A1 through competition by tranilast and N-3, with N-3 representing a more effective substrate and thus a more effective UGT1A1
inhibitor than tranilast. 20 The goal of this work was to identify derivatives of tranilast modified to increase potency and prevent the formation of the hyperbilirubinemia-promoting metabolite N-3.
Herein we report the realization of these aims through the development of the antifibrotic agent 10c (FT061).
Our initial synthetic efforts were directed at modifying the catechol portion of the tranilast structure. Previous work leading to the development of FT011 and FT023 revealed key structureactivity relationships, namely that (i) increasing the size of substituents on the catechol oxygens enhances antifibrotic activity; (ii) conversion of the carboxylic acid to an amide or its removal results in reduction of antifibrotic activity; and (iii) saturation of the double bond leads to a complete loss of antifibrotic activity. 11 Difluoromethoxy and trifluoromethoxy groups have previously been highlighted as metabolically-stable replacements for methoxy groups. [21] [22] [23] [24] We therefore investigated the effect of the introduction of fluoroalkyl groups into the tranilast structure, while maintaining the acid and double bond functionalities.
Compounds were synthesized by two main routes. Chart 1 reveals that replacement of the 4-methoxy groups of tranilast (1) with a 4-difluoromethoxy group (10a) resulted in a significant enhancement of activity. Introduction of a 5-methoxy substituent to afford 10b gave an enhancement of activity over 10a. An even greater effect was seen for replacement of both methoxy groups with difluoromethoxy groups (10c, FT061). Joining the two groups as a difluoromethylene substituent (10d) resulted in a complete loss of activity. Extension of these results to incorporate a 2-propynyl substituent, present in FT011, 11 gave an even more potent derivative 10e, indicating that previously established structure-activity results apply to this series. 11 The structure activity relationships established in this set of compounds extends to a trifluoromethyl group (10f). Additional potent antifibrotic agents were identified through incorporation of 4-tetrafluoroethoxy (10g) or 3-fluoro-4-trifluoromethoxy (10f) groups, although significant cellular toxicity was observed at higher doses of these two compounds. To better characterize the antifibrotic activity of the most promising compounds, more detailed inhibition profiles were determined for FT061 (10c), 10a and 19e at a range of concentrations. Figure 2 reveals that 10a has only a minor improvement in antifibrotic activity relative to tranilast, however both FT061 and 19e were significantly more active. To assess the renal and liver toxicity of FT061, Sprague-Dawley rats were treated with FT061 at doses of 50, 100, 200, 400 and 1000 mg/kg/d by gavage twice daily for two weeks. At the end of the study serum was collected to assess liver and renal function. Plasma levels of creatinine, urate, ALT and bilirubin from treated rats were similar to control rats (see Supporting Information).
The ability of FT061 to reduce albuminuria was assessed in a rat model of DN 12 ( Figure 4 ).
Hypertensive (m-Ren2)27 rats were exposed to streptozotocin, a drug that is cytotoxic towards .05 when compared to diabetic rat.
In conclusion a structure-activity study undertaken to identify tranilast derivatives with altered metabolism led to the discovery of FT061. FT061 is an orally-active and metabolically-stable antifibrotic agent that attenuates albuminuria in a rat model of progressive diabetes. FT061 features replacement of the metabolically labile methyl groups of the catechol of tranilast with bisdifluoromethoxy groups. This work extends previous structure-activity relationship studies 11 exploring the antifibrotic properties of tranilast to delineate further structural contributors to the antifibrotic properties of this class. FT061 is straightforward to synthesize, is a potent antifibrotic agent, appears well-tolerated in rats, and is resistant to deactivating metabolism and thus deserves further study as an agent to ameliorate the pathological effects of fibrosis.
